(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2020 (27.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/041799 A1

(51) International Patent Classification:
C07K 1/02 (2006.01) *C07K 7/06* (2006.01)
C07K 14/775 (2006.01)

(21) International Application Number:
PCT/US2019/048184

(22) International Filing Date:
26 August 2019 (26.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/722,766 24 August 2018 (24.08.2018) US
62/751,404 26 October 2018 (26.10.2018) US

(71) Applicant: **ESPERION THERAPEUTICS, INC.** [US/US]; 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108 (US).

(72) Inventor: **LALWANI, Narendra, Dhanraj**; 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108 (US).

(74) Agent: **ULLSPERGER, Chris** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES




FIG. 1

(57) **Abstract:** Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising adminstering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for administering fixed doses of ETC-1002 or ezetimibe or both to statin-intolerant patients or patients receiving statin therapy, wherein the administration reduces the likelihood of worsening diabetes in the subject or increasing the likelihood of new onset diabetes in a subject. The methods disclosed herein also include methods of treating hypercholesterolemia and cardiovascular diseases in a subject.

WO 2020/041799 A1